Related Experiment Video

Updated: Aug 9, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Implantable infusion pump management of insulin resistant diabetes mellitus

H Buchwald, E P Chute, F J Goldenberg

    Annals of Surgery
    |September 1, 1985
    PubMed

    More Related Videos

    Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

    Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

    Published on: January 4, 2018

    Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid06:21

    Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

    Published on: April 7, 2023

    Related Concept Videos

    Diabetes Mellitus: Overview and Type I Subtype01:22

    Diabetes Mellitus: Overview and Type I Subtype

    Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
    Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
    Diabetes Mellitus: Type 2 and Gestational01:22

    Diabetes Mellitus: Type 2 and Gestational

    Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
    Diabetes: Management and Pharmacotherapy01:15

    Diabetes: Management and Pharmacotherapy

    The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
    Insulin remains the cornerstone of treatment for most patients with type 1 and many...
    Insulin Formulations: Types and Delivery01:27

    Insulin Formulations: Types and Delivery

    Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
    Short-acting insulins are divided into rapid-acting...
    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...